Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CBP-174 · 1 trial · 1 indication
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Dictionary.
The investigator may use the CTCAE V5.0 to assist in the determination of severity and clinical significance.
Blood pressure measured in mmHg
Pulse rate measured per minute
respiratory rate measured in breaths per minute
tympanic temperature measured in celsius
Physical examinations includes examination in cutaneous, lymph node, head (especially of eyes) and neck, chest, abdomen, musculoskeletal and nervous systems.
Heart rate in beats per minute (Bpm) through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
R-R interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
P-R interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QRS complex measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QT interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
QTcF interval measured in millisecond through 12-lead ECG assessment. The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
Measured in g/dL. The physician will judge whether an abnormality is clinically significant.
Measured in g/dL. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in U/L. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in IU/L. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in %. The physician will judge whether an abnormality is clinically significant.
Counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Urine Occult Blood will be record as positive or negative. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Urinary leukocyte will be counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Urine erythrocytes will be counted in K/uL. The physician will judge whether an abnormality is clinically significant.
Measured in mg/dL. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in mmol/L. The physician will judge whether an abnormality is clinically significant.
Measured in seconds by coagulation tests. The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
The physician will judge whether an abnormality is clinically significant.
Measured in Units. The physician will judge whether an abnormality is clinically significant.
Measured in Units. The physician will judge whether an abnormality is clinically significant.
Recorded as positive or negative. The physician will judge whether an abnormality is clinically significant.
| Arm | Type | Description |
|---|---|---|
| CBP-174 | EXPERIMENTAL | CBP-174 oral solution |
| Placebo | EXPERIMENTAL | placebo oral solution |
| Name | Type | Description |
|---|---|---|
| CBP-174 | DRUG | CBP-174 oral solution, given once |
| Placebo | DRUG | Placebo oral solution, given once |
Inclusion Criteria: Subjects will be enrolled into the study only if they meet ALL of the following inclusion criteria: 1. Subjects are fully informed of the study, and are willing to participate in the study and sign the informed consent document prior to any procedure 2. Healthy male and female ...
CBP-174 is an investigational small molecule being studied in healthy adult subjects. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and pharmacokinetics. The drug is not approved and remains under investigation.
CBP-174 is being developed by Connect Biopharma Holdings Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CNTB. The company is conducting clinical research on this investigational small molecule.
CBP-174 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing clinical evaluation.
CBP-174 has one completed Phase 1 clinical trial, identified as NCT04811469, titled "Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults." The study enrolled 74 participants in Australia and was a randomized, double-blind, controlled trial.
CBP-174 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on healthy adult subjects to assess safety, tolerability, and pharmacokinetics, but the drug has not received regulatory approval.